Prospective, Randomized, Double- Masked Study to Evaluate the Effect of Rhopressa Versus Placebo on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-Selective Laser Trabeculoplasty (SLT)
East Coast Institute for Research
Summary
The purpose of this study is to collect data about how Rhopressa affects IOP in patients who have had an SLT procedure in both eyes.
Description
This is a prospective, randomized, double-masked, placebo controlled (artificial tears), single center study. The study population will include seventy (n=70) subjects with POAG or ocular hypertension who have undergone SLT and may benefit from additional IOP reduction. If individuals are a candidate for treatment with Rhopressa (netarsudil) 0.02% ophthalmic solution post-SLT, they can potentially be included in the trial. The study duration per subject is expected to be 6 weeks (or up to 12 weeks if washout is required for previous IOP lowering treatment) with three scheduled study visits. W…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Age ≥ 18 years 2. Documented diagnosis of bilateral POAG or ocular hypertension as determined by the investigator based on medical record review. 3. At Screening (V1), the subject completed SLT in both the eyes within the last 90 days. 4. Mean diurnal IOP of 16 to 28 mmHg at Randomization (V2 ) 5. At Randomization (V2), in the opinion of the investigator, subject may benefit from additional IOP reduction in the study eye and is a candidate for treatment with Rhopressa 6. At Randomization (V2), if treated with IOP-lowering medication(s) in either eye prior to SLT, subjec…
Interventions
- DrugNetarsudil ophthalmic solution 0.02%
Apply one drop in each eye every evening
- DrugArtificial tears
Apply one drop in each eye every evening
Location
- East Coast Institute for Research at Florida Eye SpecialistsJacksonville, Florida